Global Lung Cancer Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025

PrintEmail
April 2019 - 93 Pages - From $2,750 (15% discount available)
Description

The report cover may be different from the image shown.

The product will be delivered by email. If you have any question, want to preview some sample pages, or ask for custom research, please contact us. You can also check with us for possible discount. It is possible now to buy a part of the report in terms of chapter, section, data table or figure.

License Type

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

"Global Lung Cancer Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[93 pages report] This market research report includes a detailed segmentation of the global lung cancer drugs market by disease type (small cell lung cancer {SCLC} and non-small cell lung cancer {NSCLC}), by molecule type (small molecules and biologics), by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Lung Cancer Drugs Market
Infoholic’s market research report predicts that the “Global Lung Cancer Drugs Market” will grow at a CAGR of 13.6% during the forecast period. The market has witnessed steady growth in the past few years with the introduction of novel products, which have augmented the acceptance of immunotherapy drugs in the market. The market is fueled by upsurge in the incidence of lung cancer cases across the globe – owing to increasing diagnosis rate and mainly due to increasing tobacco consumption, increase in the lung cancer treatment rates, increasing rate of effective drug approvals as first-line therapies, strategic deals to develop new products, increasing R&D spending, and rapid industrialization leading to increased pollution.

The leading global pharmaceutical companies are focusing on product approvals as first-line treatment therapy and combination treatment with chemotherapy, collaborations, and regulatory submission of already matured cancer treatments in the developing countries as a major strategy to increase their revenue. Many of the global players are also focusing on providing home infusion services in the developed markets with secured and safe cold chain logistic infrastructure. This Direct-to-Patient (DTP) strategy is also helping market players to expand their patient volumes and thus the overall revenues globally. The market generates the revenue from the key players operating in this field and some of them includes, F. Hoffmann-La Roche Ltd, Bristol–Myers Squibb, Janssen, Amgen, AstraZeneca PLC, Pfizer, Inc., Eli Lilly & Company Ltd, and Novartis AG.
According to Infoholic Research analysis, North America accounted for the largest share of the global lung cancer drugs market in 2018 and will retain high position during the forecast period 2019–2025. According to WHO, cancer accounted for an estimated 9.6 million deaths in 2018 and the most common cancer among all types is lung cancer (2.09 million cases). An estimated 234,030 new cases of lung cancer were diagnosed in 2018, representing about 13% of all cancer diagnoses in the country.
Europe is the second major shareholder of the global lung cancer drrugs market. There were an estimated 3.91 million new cases of cancer and 1.93 million deaths from cancer in 2018. Lung cancer is the third most common cancer type of cancer (470,000) after the female breast cancer and colorectal cancer (500,000). In UK, around 46,700 new lung cancer cases are recorded annually and it is the third most common cancer. The Asia Pacific is expected to grow at high double digit CAGR during the forecast period, owing to factors such as increasing prevalence of cancer cases, growing healthcare expenditure, and increased healthcare awareness.
By Disease Type:
• Small cell lung cancer (SCLC)
• Non-small cell lung cancer (NSCLC)
The non-small cell lung cancer segment occupied the largest share in 2018 and is expected to grow at mid-double digit CAGR during the forecast period. The increasing incidence and prevalence of non-small cell lung cancer and rapid industrialization makes the segment fastest growing during the forecast period 2019–2025.
By Molecule Type:
• Small molecules
• Biologics
In 2018, the small molecules segment occupied the largest share and biologics is expected to grow at a high CAGR during the forecast period due to increasing adoption of biologics, strong pipeline targeting first-line treatments, and recent product approvals.
By Regions:
• North America
• Europe
• APAC
• RoW
North America is dominant in the global lung cancer drugs market followed by Europe and Asia Pacific. The significant share of the North America market comes from the US due to the availability of favorable reimbursement policies.
Lung Cancer Drugs Market Research Competitive Analysis – The global lung cancer drugs market has massive growth opportunities in both developed and developing regions. Many companies are concentrating on new approvals, collaborations, and development of new drugs to treat lung cancer due to increase in the incidence of cancer and the need for advanced treatments. For instance, the European Commission has approved brigatinib (Alunbrig) developed by Takeda Pharmaceutical in November 2018 to treat adult patients with ALK-positive non–small cell lung cancer (NSCLC) who were previously treated with crizotinib (Xalkori). FDA approved durvalumab (Imfinzi) developed by AstraZeneca Inc. in February 2018 for the treatment of unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. In addition, other leading vendors are focusing in investing huge on research and development activities to develop new products to obtain high share in the market.

Key Vendors:
• F. Hoffmann-La Roche Ltd.
• AstraZeneca PLC
• Bristol–Myers Squibb
• Pfizer, Inc.
• Eli Lilly and Company Ltd.
• Novartis AG
Key Competitive Facts
• Increasing incidence of the disease globally, promising drug pipeline, and enormous R&D activities for the lung cancer drug development are the major factors driving the market growth.
• The pipeline of oncology drugs in the clinical development has expanded by 45% over the past 10 years; 87% of the late-stage pipeline is targeted therapies, which include small molecule protein kinase inhibitors and biologic monoclonal antibodies.
Benefits – The report provides complete details about the sub-segments of the lung cancer drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals and to analyze before investing or expanding the business in this market.

Key Takeaways:
• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of lung cancer drugs industry.
• Factors influencing the growth of the lung cancer drugs market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the lung cancer drugs market in both developed and developing regions.
• Key insights related to major segments of the lung cancer drugs market.
• Latest market trend analysis impacting the buying behavior of the consumers.
Key Stakeholders

" "Table of Contents
1 Industry Outlook
1.1 Industry Overview
1.1.1 Top Pharma Drugs by Sales ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of the Lung Cancer Drugs Market
3.4 Related Markets
3.4.1 Over-the-Counter (OTC) Drugs
3.4.2 Respiratory Drugs
3.4.3 Diabetes Drugs
4 Market Outlook
4.1 Oncology Drugs Approved by FDA (2014–2018)
4.2 Market Segmentation
4.3 PEST Analysis
4.4 Porter 5 (Five) Forces
5 Market Characteristics
5.1 DRO – Global Lung Cancer Drugs Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing incidence of lung cancer cases across the globe
5.1.1.2 Recent drug approvals and collaborations to develop new products
5.1.2 Opportunities
5.1.2.1 Increasing R&D spending for the development of new products
5.1.2.2 Rapid industrialization leading to increasing pollution
5.1.3 Restraints
5.1.3.1 High treatment cost
5.1.3.2 Patent loss of key drugs to slow down the pace of the market
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Disease Types: Market Size and Analysis
6.1 Overview
6.2 Small Cell Lung Cancer (SCLC)
6.3 Non-Small Cell Lung Cancer (NSCLC)
7 Molecule Type: Market Size and Analysis
7.1 Overview
7.2 Small Molecules
7.3 Biologics
8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape
9.1 Overview
10 Vendor Profiles
10.1 F. Hoffmann-La Roche Ltd.
10.1.1 Overview
10.1.2 Business Units
10.1.3 Geographic Revenue
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 AstraZeneca PLC
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Pfizer, Inc.
10.3.1 Overview
10.3.2 Business Units
10.3.3 Geographic Revenue
10.3.4 Business Focus
10.3.5 SWOT Analysis
10.3.6 Business Strategies
10.4 Eli Lilly & Company Ltd
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Revenue
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 Novartis AG
10.5.1 Overview
10.5.2 Business Units
10.5.3 Geographic Revenue
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategy
11 Companies to Watch For
11.1 Bristol-Myers Squibb
11.1.1 Overview
11.2 GlaxoSmithKline plc
11.2.1 Overview
11.3 Merck & Co., Inc.
11.3.1 Overview
11.4 Sanofi S.A.
11.4.1 Overview
11.5 Celgene Corporation
11.5.1 Overview
12 Annexure
12.1 Abbreviations

" "Tables

TABLE 1 TOP 10 PHARMA COMPANIES BY SIZE OF PIPELINE 9
TABLE 2 TOP 10 PHARMA COMPANIES BY REVENUE ($BILLION) 10
TABLE 3 TOP PHARMA DRUGS BY SALES ($MILLION) 11
TABLE 4 LIST OF ONCOLOGY DRUGS APPROVED (2017 & 2018) 21
TABLE 5 GLOBAL LUNG CANCER DRUGS MARKET REVENUE BY REGIONS, 2018–2025 ($BILLION) 44
TABLE 6 OTHER VENDORS OF LUNG CANCER DRUGS MARKET 52
TABLE 7 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 53
TABLE 8 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 53
TABLE 9 ASTRAZENECA PLC: PRODUCT OFFERINGS 58
TABLE 10 ASTRAZENECA PLC: RECENT DEVELOPMENTS 58
TABLE 11 PFIZER INC.: PRODUCT OFFERINGS 63
TABLE 12 PFIZER INC.: RECENT DEVELOPMENTS 64
TABLE 13 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 68
TABLE 14 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 68
TABLE 15 NOVARTIS AG: PRODUCT OFFERINGS 74
TABLE 16 NOVARTIS AG: RECENT DEVELOPMENTS 75
TABLE 17 BRISTOL-MYERS SQUIBB: SNAPSHOT 81
TABLE 18 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS 81
TABLE 19 GLAXOSMITHKLINE PLC: SNAPSHOT 84
TABLE 20 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 85
TABLE 21 MERCK & CO., INC.: SNAPSHOT 86
TABLE 22 MERCK & CO., INC.: RECENT DEVELOPMENTS 86
TABLE 23 SANOFI: SNAPSHOT 88
TABLE 24 SANOFI: RECENT DEVELOPMENTS 89
TABLE 25 CELGENE CORPORATION: SNAPSHOT 90
TABLE 26 CELGENE CORPORATION: RECENT DEVELOPMENTS 91

" "Charts

CHART 1 PHARMACEUTICAL DRUGS BY SALES, 2018 11
CHART 2 RESEARCH METHODOLOGY OF GLOBAL LUNG CANCER DRUGS MARKET 15
CHART 3 GLOBAL LUNG CANCER DRUGS MARKET REVENUE, 2018–2025 ($BILLION) 18
CHART 4 SEGMENTATION OF GLOBAL LUNG CANCER DRUGS MARKET 25
CHART 5 PEST ANALYSIS OF GLOBAL LUNG CANCER DRUGS MARKET 25
CHART 6 PORTER 5 FORCES ON GLOBAL LUNG CANCER DRUGS MARKET 26
CHART 7 MARKET DYNAMICS – DRO ANALYSIS 28
CHART 8 DRO – IMPACT ANALYSIS OF GLOBAL LUNG CANCER DRUGS MARKET 31
CHART 9 KEY STAKEHOLDERS 32
CHART 10 GLOBAL LUNG CANCER DRUGS MARKET BY DISEASE TYPE SEGMENTATION, 2018 (%) 34
CHART 11 GLOBAL LUNG CANCER DRUGS MARKET BY DISEASE TYPE SEGMENTATION, 2025 (%) 35
CHART 12 GLOBAL SMALL CELL LUNG CANCER MARKET FORECAST, 2018–2025 ($BILLION) 36
CHART 13 GLOBAL NON-SMALL CELL LUNG CANCER MARKET FORECAST, 2018–2025 ($BILLION) 37
CHART 14 GLOBAL LUNG CANCER DRUGS MARKET BY MOLECULE TYPE SEGMENTATION, 2018 (%) 38
CHART 15 GLOBAL LUNG CANCER DRUGS MARKET BY MOLECULE TYPE SEGMENTATION, 2025 (%) 39
CHART 16 GLOBAL SMALL MOLECULES MARKET FORECAST, 2018–2025 ($BILLION) 40
CHART 17 GLOBAL BIOLOGICS MARKET FORECAST, 2018–2025 ($BILLION) 42
CHART 18 GLOBAL LUNG CANCER DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2018 (%) 43
CHART 19 GLOBAL LUNG CANCER DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2025 (%) 43
CHART 20 LUNG CANCER DRUGS MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($BILLION) 45
CHART 21 LUNG CANCER DRUGS MARKET REVENUE IN EUROPE, 2018–2025 ($BILLION) 47
CHART 22 LUNG CANCER DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($BILLION) 48
CHART 23 LUNG CANCER DRUGS MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($BILLION) 50
CHART 24 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 54
CHART 25 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 55
CHART 26 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE 55
CHART 27 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 56
CHART 28 ASTRAZENECA PLC: OVERVIEW SNAPSHOT 59
CHART 29 ASTRAZENECA PLC: BUSINESS UNITS 60
CHART 30 ASTRAZENECA PLC: GEOGRAPHIC REVENUE 61
CHART 31 ASTRAZENECA PLC: SWOT ANALYSIS 62
CHART 32 PFIZER INC.: OVERVIEW SNAPSHOT 65
CHART 33 PFIZER INC.: BUSINESS UNITS 66
CHART 34 PFIZER INC.: GEOGRAPHIC REVENUE 66
CHART 35 PFIZER INC: SWOT ANALYSIS 67
CHART 36 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 71
CHART 37 ELI LILLY & COMPANY LTD.: BUSINESS UNITS 71
CHART 38 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 72
CHART 39 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 73
CHART 40 NOVARTIS AG: OVERVIEW SNAPSHOT 77
CHART 41 NOVARTIS AG: BUSINESS UNITS 77
CHART 42 NOVARTIS AG: GEOGRAPHICAL REVENUE 78
CHART 43 NOVARTIS AG: SWOT ANALYSIS 79

 

"

Reviews

There are yet no reviews for this product.